Tedatioxetine
Alternative Names: LU-AA24530Latest Information Update: 23 May 2016
Price :
$50 *
At a glance
- Originator Lundbeck A/S
- Developer Lundbeck A/S; Takeda
- Class Antidepressants; Anxiolytics; Piperidines
- Mechanism of Action Biogenic monoamine uptake inhibitors; Serotonin 2C receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Generalised anxiety disorder; Major depressive disorder
Most Recent Events
- 10 May 2016 Discontinued - Phase-I for Generalised anxiety disorder in USA, Japan (PO)
- 10 May 2016 Discontinued - Phase-I for Major depressive disorder in USA, Japan (PO)
- 30 Jul 2015 Tedatioxetine is still in phase I trials for Major depressive disorders and Generalised anxiety disorder in USA and Japan